We describe the clinical case of a 15-year-old boy presenting with acute onset of left hemiplegia due to ischemic stroke, successfully treated with systemic thrombolysis with t-PA. Diagnosis and management of paediatric stroke can be difficult in the Emergency Departement (ED), because of the rarity of the disease and because of the absence of clear guidelines guaranteeing a uniform treatment.
is "a clinical syndrome of rapidly developing focal or global disturbance of brain function lasting more than 24 hours". This definition is not congenial in children, because of shaded neurological symptoms or of overlapping clinical presentations of several clinical syndromes. Moreover, children and adolescents with stroke have notable differences in presentation compared to adults. Children with symptoms compatible with a transient ischemic attack (TIA) could have a brain infarction revealed by brain imaging despite the transient nature of their symptoms. Children with cerebral venous sinus thrombosis can commonly present headache or seizures at onset. "Stroke-like episodes" without a clear vascular cause may occur in migraine or metabolic disease (2) . Stroke type in paediatric patients also varies considerably. In Western countries, 80% to 85% of strokes among adults are ischemic, 15-20% are haemorrhagic. In children, more than 55% of strokes are ischemic, 45% are haemorrhagic. The estimated annual stroke incidence rate for children in the main literature reviews is 2.1-2.7 per 100 000 per year for strokes, even if the frequency of ischemic stroke appears to be greater than previously suggested (3). In the underage population, peak age for ischemic stroke is in the first year of life, representing a third of the cases. Although there have been a few reports of the use of tissue plasminogen activator (tPA) in children with ischemic stroke (4-6), safety and efficacy data for either intravenous or intra-arterial thrombolysis in children with acute arterial occlusion are lacking. As in adults receiving tPA, it is likely that its delayed administration in children will lead to an unacceptable rate of intracerebral haemorrhage. If tPA is considered, it is imperative to adhere to the accepted time limits used in adults: administration of intravenous tPA within 3 hours of stroke onset and intra-arterial tPA within 6 hours of stroke onset for anterior circulation strokes. This is a serious limitation in children with stroke because the awareness of the severity and consequent rapidness in seeking help is much later than in older patients with stroke. Even tPA dosage is subject to discussion, there is some evidence that a lower-dose tPA regimen might well be effective in children, with a remarkable complications reduction (7) . If this observation is valid, it could be the startpoint for additional trials designed to improve safety usage of tPA in underage patients.
Conclusions
The treatment of stroke in infants and children is both important and understudied. Sometimes the treatment decisions are relatively clear, but more often the lack of randomized controlled clinical trials makes it difficult to know the clinical action to take. Given the lack of clear guidelines, every single clinical case should be considered singularly. If the clinical suspect is sustained by laboratory and instrumental findings and if the clinical onset is severe, considering that a conventional therapy could lead to high morbidity and residual disability, administration of tPA for a systemic thrombolysis should be at least considered.
Materiale protetto da copyright. Non fotocopiare o distribuire elettronicamente senza l'autorizzazione scritta dell'editore. Several inherited prothrombotic risk factors were examinated, in particular the ones that are most commonly associated to stroke in the peadiatric population (1), such as factor V, factor II, and MTHFR mutations, and antiphospholipid antibodies; the performed panel was entirely normal. Vital parameters were stable during hospitalization. Daily physiotherapy was performed obtaining good motor recovery with a decrease in NIHSS from 14 to 3 by the 7° day and Barthel index rose from 10/100 (value at time of admission) to 85/100 (value at time of discharge), demonstrating an appreciable gradual improvement of residual authonomy. At dismission the patient presented a mild motor deficiency at the left lower limb with a moderate left grab deficiency, normal Mingazzini I, unstable Mingazzini II, NIHSS 2. The patient was discharged after 19 days with a diagnosis of "right MCA ischemic stroke with PFO with left-to-right shunt" and transferred to a rehabilitation care centre.
Discussion
Haemorrhagic and ischemic stroke is a rare disease in the paediatric population, yet there has been a recognised increase in recent years. Diagnosis and management can be difficult due to the diversity of underlying risk factors and to the absence of guidelines guaranteeing a uniform treatment. To achieve a correct management of these difficult clinical cases and to obtain an off-label administration of a drug approved from EMEA for different patients, it must be possible for the Emergency Physician to get in touch with the Hospital Administration and regional Ethic Committee. When the go-ahead is obtained, clear explanation of potential benefits and risk of the procedure should be explained to the patients and to the parents or legal guardians of the child. After which, both the parents should give their informed consent and the child should give his/her informed assent, and an informed consent form should be signed. Our clinical experience achieved excellent results, with a complete return to normal neurological function and no residual loss of function. This should point us towards considering an off-label therapy. 
